comprehensive -WSS

comprehensive

author：focus 2025-10-01 00:30:32 - browse：11374

Balance innovation — Medicare laid out in the greatest detail yet how it will choose which drug prices it will negotiate in its brand-new program, and how it will figure out what the government’s opening offer will be. Adobe

WASHINGTON — Medicare laid out Wednesday in the greatest detail yet how it will choose which drug prices it will negotiate in its brand-new program, and how it will figure out what the government’s opening offer will be.

Democrats outlined some parts of the process in the Inflation Reduction Act that passed Congress last August, but the details of how drugs will be selected and what factors will be considered have been vague until now. Though the actual negotiated prices won’t take effect for years, Medicare officials must announce the first 10 drugs they’ll negotiate over by Sept. 1.

The guidance clarifies that the agency will choose the 50 pharmacy drugs that cost Medicare the most money, based on gross expenditures. If drugs have the same cost to the program, then the one that has been approved longer will be ranked higher.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Alkermes shareholders re
Next article： Rune Labs, whose app tracks Parkinson's symptoms, raises $12M

WSS

Mayo Clinic partners with supercomputer AI firm Cerebras at JPM

Profiling embryos to choose those with higher IQs is almost a reality

JPM 2024 Review: Hope for the XBI, deals from J&J, Merck, GSK

Rune Labs, whose app tracks Parkinson's symptoms, raises $12M

Rune Labs, whose app tracks Parkinson's symptoms, raises $12M

Life science postdocs should get big pay hike, NIH panel says

hotspot

comprehensive

hotspot

What does generative AI mean for health care? We asked experts

Does Paxlovid work in people vaccinated against Covid

Cancer drug shortages should be causing more outrage

JPM 2024: Biotech’s most prolific dealmaker sees a rosy 2024

The high cost of giving birth even with insurance

Nonprofit, backed by Microsoft, to certify AI tools in health care

Hepatitis C has a cure — but many Americans still lack access to it

Mayo Clinic partners with supercomputer AI firm Cerebras at JPM

Medicare details structure of new drug price negotiation program

Profiling embryos to choose those with higher IQs is almost a reality

focus

Arena BioWorks launches in Cambridge to speed drug discovery

Readout Newsletter: Cytokinetics and Novartis' starcrossed tale

Gene therapy denied for Afghan refugee whose father aided U.S.

Allen Institute goes after foundational questions, CEO Costa says

Merck to acquire Harpoon Therapeutics for $680 million

Allen Institute goes after foundational questions, CEO Costa says

leisure time

leisure time

hotspot

hotspot